Can Vertex Pharmaceuticals Recover From Its Latest Setback?
Everyone who was already nervous about the road ahead of Vertex Pharmaceuticals (NASDAQ: VRTX) got another reason to worry recently. On Jun. 10, 2021, the company told investors its second attempt at treating a rare lung disease didn't perform much better than the first time around. Without any internally discovered drugs in late-stage testing, the company's going to be heavily reliant on revenue from a limited population of cystic fibrosis patients.
Shares of this biotech stock have been hammered lately even though a partnership with CRISPR Therapeutics (NASDAQ: CRSP) could produce an important new revenue stream in the foreseeable future. Can shares of Vertex Pharmaceuticals recover or are this biotech stock's best days already behind it?
Image source: Getty Images.
Source Fool.com
